Tres Alchemix raises $4.4M in Series A funding to accelerate AI-driven drug discovery

26 September 2025

Tres Alchemix, an early-stage biotechnology company applying artificial intelligence (AI) to drug discovery, today announced it has closed a $4.4 million Series A financing. The round was led by DNX Ventures, with participation from existing investor Waseda University Ventures.

The funding will accelerate development of Tres Alchemix’s predictive AI platform and support the opening of a new laboratory at The Oxford Science Park, a hub of world-leading science and technology companies.

Co-founded in 2023 by three DPhil (PhD) graduates of the University of Oxford, Tres Alchemix is developing advanced technologies that integrate multi-omic and multimodal big data with proprietary quantum-chemical calculation methods to build predictive models of biological and biochemical processes in the human body. These human in silico models forecast how new drugs will behave in the body, capturing both therapeutic effects and side effects. This capability enables the design of novel small-molecule candidates that maximise efficacy while minimising risk.

L-R: Dr Hisashi Hashimoto (co-founder & CEO), Ellen Zunker (COO), Dr Takuma Morimoto (co-founder & CSO), Dr Masato Inoue (CPO)

While headquarters remain in Fukuoka, Japan, Tres Alchemix has since established a research and development subsidiary in Oxford in 2024. With the additional funding, it is further strengthening its regional operations. Tres Alchemix is initially focusing on oncology and will commence the design of novel hit compounds from its Oxford laboratory.

Hisashi Hashimoto, Co-founder and CEO of Tres Alchemix, said: “We believe our technology can be a game changer for the drug-discovery field.Our models can accurately predict drug effects and potential side effects and can even propose new compounds tailored to disease biology. This allows us to compress, or even bypass, the time-consuming hit-discovery phase while lowering the risk of late-stage clinical failure.”

Akira Kurabayashi, Managing Partner and Head of Japan at DNX Ventures, said: “DNX are excited to lead the investment in Tres Alchemix and their human in silico models, which simulate drug behaviour in the body and enable high-precision predictions of both therapeutic effects and potential risks.”

Yoshiki Shiraishi, Partner at DNX Ventures, said: “The three co-founders, who met at the University of Oxford, bring together expertise in medicine, computer science, and quantum chemical calculations. We believe that the innovative methodology developed by these three (“Tres”) scientists will play a leading role in transforming global drug development.”

Find out more about Tres Alchemix

Read other news articles

News